Hutchmed's (HKG:0013) Tagrisso and Orpathys combination showed a "favorable" response during a phase 2 trial for epidermal growth factor receptor-mutated non-small cell lung cancer.
Orpathys and Tagrisso are MET tyrosine kinase inhibitors, according to a Wednesday filing with the Hong Kong Exchange.
Shares increased 1% during Wednesday's trading.
Price (HKD): $30.40, Change: $+0.40, Percent Change: +1.33%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments